Intranasal etripamil developer Milestone Pharmaceuticals has announced the appointment of Lorenz Muller as Chief Commercial Officer. Muller was most recently VP, Marketing at Exact Sciences Corporation and has previously held positions at Daiichi Sankyo, CV Therapeutics , and Merck.
In August 2017, Milestone announced that it had raised $55 million for Phase 3 development of intranasal etripamil for the treatment of paroxysmal supraventricular tachycardia (PSVT). The company had announced positive results from the Phase 2 NODE-1 study of etripamil in PSVT patients in May 2017.
Milestone President and CEO Joseph Oliveto commented, “Lorenz brings a track record of success in the cardiovascular space which is ideally suited for Milestone and the development of etripamil. Lorenz’s hiring follows recent and ongoing consultation with the FDA which provides confidence to undertake our pivotal Phase 3 study (NODE-301) and to build commercial plans for what could become the only patient-administered treatment for the acute termination of paroxysmal supraventricular tachycardia (PSVT) episodes.”
Muller said, “Treatment of PSVT with etripamil represents a tremendous opportunity to address an unmet medical need and tap into a potentially significant, unrealized market. The ability to manage PSVT episodes quickly and conveniently wherever and whenever they occur is paradigm-changing and may result in immediate relief for patients, as well as a significant reduction in health care costs. I’m pleased to join the Milestone team as we build the commercial foundation for etripamil.”
Read the Milestone Pharmaceuticals press release.
